MedTrace Logo

Safety and Efficacy Study of DCVax-Direct in Solid Tumors

NCT01882946 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2015-10-07

No results posted yet for this study

Summary

The study comprises a Phase I component during which the optimal dose of DCVax-Direct for the treatment of solid tissue tumors will be identified, followed by a Phase II component to determine if the injection of DCVax-Direct into selected solid tissue tumors has the ability to reduce tumor growth.

Conditions

Interventions

BIOLOGICAL

DCVax-Direct

Autologous, activated dendritic cells for intratumoral injection

Sponsors & Collaborators

  • Northwest Biotherapeutics

    lead INDUSTRY

Principal Investigators

  • Marnix Bosch, MBA, PhD · Northwest Biotherapeutics

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2016-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01882946 on ClinicalTrials.gov